In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics has said it expects gross proceeds of $300 million from its Nasdaq ...
The Spanish distie will now be able to provide its partners with access to Apogee's technology solutions, such as digital workspace, managed IT services, print services management, and outsourced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results